PFLUGERVILLE, TEXAS: HOW TO KNOW WHEN YOU’RE IN PFLUGERVILLE
Will the real Pflugerville please stand up?
Enter a keyword to search
Editor in Chief of Site Selection Magazine
Adam Bruns is editor in chief and head of publications for Site Selection magazine, where he served as managing editor from February 2002 until fall 2023. In the course of reporting hundreds of stories for Site Selection, Adam has visited companies and communities around the globe. A St. Louis native who grew up in the Kansas City suburbs, Adam is a 1986 alumnus of Knox College, and resided in Chicago; Midcoast Maine; Savannah, Georgia; and Lexington, Kentucky, before settling in Greater Atlanta with his wife and daughter.
e-mail: Adam.Bruns@conway.com
Will the real Pflugerville please stand up?
Predictions: Not a Game We Play
Texas continues to offer the best environment for corporate investment. One company’s site selection story embodies the state’s advantages.
Louisville retains the top spot in our annual examination of project activity in every metropolitan and micropolitan area along the river’s 981-mile route.
Indices point to the globe’s best-performing ports, plus expert insights into U.S. Foreign-Trade Zones and how they help with tariffs.
Portrayed perpetually in bounce-back mode, some industrial regions in the Great Lakes are using their very resilience to propel them to the lead instead of playing catch-up.
In an environment disrupted by U.S. tariffs, it can be reassuring to recall the sentiments expressed on a challenge coin given to me by leaders of the Canadian Consulate in Atlanta at a recent event held at the Georgia state capitol to celebrate ties between the state and Canada.
Want to know why Illinois leads America in quantum computing? Check out what’s happening at IQMP.
Based on pure hype, you might think the top sector represented among the 5,000 fastest-growing companies in the United States would be the Artificial Intelligence & Data category.
Moved in part by “America First” policy actions and tariffs from the White House that include Most Favored Nation pricing, big biopharma is bringing more than $370 billion of investment stateside.